Transient elastography compared to serum markers to predict liver fibrosis in a cohort of Chinese patients with chronic hepatitis B

Abstract

Background and Aim: Liver stiffness measurement (LSM) using transient elastography (FibroScan) is a useful tool to assess fibrosis in various chronic liver diseases. However, studies were mainly performed in Western countries and largely focused on chronic hepatitis C (CHC). We therefore carried out a multicenter study to validate the accuracy of LSM in the assessment of liver fibrosis in a large cohort of Chinese patients with chronic hepatitis B (CHB). Methods: We compared LSM results to histological staging and serum fibrosis markers (five direct markers, APRI and FIB-4) using Spearman correlation analysis and area under receiver operating characteristic (ROC) curves (AUROCs). Results: Four hundred sixty-nine patients were enrolled and eligible for statistical analysis. LSM in F0 to F4 was 5.5 ± 1.7, 5.8 ± 2.2, 7.6 ± 3.4, 14.5 ± 10.8, and 22.3 ± 13.6 kPa, respectively (correlation with fibrosis stage r = 0.522, P < 0.001). AUROC for LSM to correctly allocate patients to histological fibrosis stage ≥ F2, ≥ F3, and F4 was 0.82, 0.88, and 0.90, respectively. LSM outperformed serum fibrosis markers for detection of fibrosis F ≥ 2 and F4. Patients with ALT levels 1-5x and > 5x the upper limit of normal values had significantly higher stiffness values than stage-matched patients with normal alanine aminotransferase. Conclusion: Transient elastography is a reliable noninvasive technique to predict significant liver fibrosis in Chinese patients with CHB, being superior to current biomarker panels. However, enhanced inflammatory activity can lead to elevated stiffness values unrelated to histological fibrosis stage.

A diagnostic algorithm for assessment of liver fibrosis by liver stiffness measurement in patients with chronic hepatitis B

“…In our cohort of patients with CHB, we demonstrated the good performance of LSM in staging significant fibrosis (S3‐S6) and advanced fibrosis (S4‐S6). Our result is in agreement with previous studies . The optimal cut‐offs in our study of patients with CHB are also comparable to those identified in other studies …”

Evaluation of eLIFT for Non-invasive Assessment of Liver fibrosis and Cirrhosis in Patients with Chronic Hepatitis B Virus Infection

“…A study by Jia et al . showed that liver elastometry got high AUROCs of 0.82, 0.88, and 0.90 for the diagnoses of advanced fibrosis, severe fibrosis, and cirrhosis, respectively 13 . Recently, the study by Shi et al .…”

Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance

“…Patients with moderate‐to‐severe inflammation (A3 or higher) and/or fibrosis (F2 or higher) can be considered for antiviral therapy . Noninvasive methods may be used in lieu of liver biopsies to assess for severity of fibrosis and/or inflammation . Liver stiffness measurements (elastrography) are more accurate than serum fibrosis panels (e.g.…”

“…aspartate aminotransferase [AST] to platelet ratio index or FIB‐4) in predicting significant or advanced fibrosis . Noninvasive methods overestimate fibrosis if high levels of necroinflammation, as reflected by elevated ALT, are present …”